Home/Filings/4/0001209191-19-022659
4//SEC Filing

YAO TONY DUNG LING 4

Accession 0001209191-19-022659

CIK 0001357874other

Filed

Apr 1, 8:00 PM ET

Accepted

Apr 2, 5:19 PM ET

Size

20.9 KB

Accession

0001209191-19-022659

Insider Transaction Report

Form 4
Period: 2019-04-01
Transactions
  • Conversion

    Common Stock

    2019-04-01$13.60/sh+36,946$502,46636,946 total(indirect: By ArrowMark Life Science Fund, LP)
  • Conversion

    Series B Preferred Stock

    2019-04-01244,5720 total(indirect: By ArrowMark Life Science Fund, LP)
    Common Stock (114,570 underlying)
  • Conversion

    Common Stock

    2019-04-01+4,4504,450 total(indirect: By LLC)
  • Conversion

    Series B Preferred Stock

    2019-04-019,5000 total
    Common Stock (4,450 underlying)
  • Conversion

    Convertible Promissory Note

    2019-04-010 total(indirect: By ArrowMark Life Science Fund, LP)
    Exercise: $13.60Common Stock (36,946 underlying)
  • Conversion

    Series B Preferred Stock

    2019-04-019,5000 total(indirect: By LLC)
    Common Stock (4,450 underlying)
  • Conversion

    Common Stock

    2019-04-01+4,4504,450 total
  • Conversion

    Common Stock

    2019-04-01+114,570151,516 total(indirect: By ArrowMark Life Science Fund, LP)
Footnotes (4)
  • [F1]The Series B Preferred Stock automatically converted into the common stock of Precision BioSciences, Inc. (the "Issuer") on a 2.134686-to-1 basis (after giving effect to the Issuer's previously completed reverse stock split) upon the closing of the Issuer's initial public offering (the "IPO").
  • [F2]These securities are held of record by the ArrowMark Life Science Fund, LP (the "ArrowMark Fund"). ArrowMark Colorado Holdings LLC ("ArrowMark Colorado") is an investment advisor to the ArrowMark Fund. The reporting person is employed as a portfolio manager for ArrowMark Colorado and has direct voting and dispositive control over the shares held by the ArrowMark Fund. The reporting person disclaims beneficial ownership of these securities except to the extent of any pecuniary interest therein.
  • [F3]These securities are held of record by the THB Iron Rose, LLC Life Science Portfolio (the "THB Fund"). ArrowMark Colorado is an investment advisor to the THB Fund. The reporting person is employed as a portfolio manager for ArrowMark Colorado and has direct voting and dispositive control over the shares held by the THB Fund. The reporting person disclaims beneficial ownership of these securities except to the extent of any pecuniary interest therein.
  • [F4]On March 1, 2019, the ArrowMark Fund acquired a convertible promissory note in the principal amount of $500,000 (the "2019 Note") from the Issuer. Effective upon the closing of the IPO on April 1, 2019, the 2019 Note, including accrued interest, converted into 36,946 shares of the Issuer's common stock at a price per share equal to $13.60, which represented 85% of the price per share in the IPO.

Issuer

PRECISION BIOSCIENCES INC

CIK 0001357874

Entity typeother

Related Parties

1
  • filerCIK 0001771680

Filing Metadata

Form type
4
Filed
Apr 1, 8:00 PM ET
Accepted
Apr 2, 5:19 PM ET
Size
20.9 KB